Register Login

PLASTIC RECONSTRUCTIVE AND REGENERATIVE SURGERY

Original article

Vol. 24 No. 4 (2026): Blood Transfusion 4-2026 (July-August)

Comparison between cold-stored platelets treated with riboflavin and UV light versus untreated cold-stored platelets

Authors

Teresa Jimenez-Marco ORCID , Natalia Torres-Reverte , Miguel Quetglas-Oliver ORCID , Daniel Morell-Garcia , Carme Ballester-Servera ORCID

Key words: Platelets, Cold Temperature, Riboflavin, UV Light
Doi: 10.2450/BloodTransfus.1268
Collection, production and storage of blood components
Publication Date: 2026-04-16

Abstract

Background - Riboflavin and UV light-based pathogen reduction technology (PRT) and cold-stored platelets (CSP) have a significant impact on platelet (PLT) function. The aim of this study is to determine whether the use of both methods is beneficial.

Materials and methods - Twenty buffy coat (BC) PLT concentrates were grouped into 10 type-matched pairs, which were pooled and split into 10 non-PRT-treated PLTs and 10 PRT-treated PLTs, diluted in platelet additive solution (PAS-E) and leukoreduced. Both groups were cold-stored at 2-6ºC without agitation for 14 days (non-PRT CSP and PRT CSP). Hemostatic function and metabolic parameters were monitored on day 1 pre-refrigeration and on days 3, 7 and 14 of cold storage.

Results - No swirling and no aggregates were observed at any time in either group after cold storage for 14 days. PRT CSP were less metabolically active (with better pH, lower lactate, lower pCO2 and higher pO2) than non-PRT CSP (p<0.001) after 14 days of cold storage. PRT CSP and non-PRT CSP resulted in faster clot formation over storage (p<0.001). Clot strength was reduced under optimal levels on day 14 in the PRT CSP (p<0.001).

Discussion - The enhanced hemostatic PLT function achieved by CSP, i.e., faster clot formation, is also maintained by riboflavin and UV light treatment. The combination of riboflavin and UV light-based PRT and CSP has the added benefit of reducing platelet metabolism, which may have a positive effect on PLT viability. Further research is required to assess whether the in vitro benefits of combining PRT and CSP are confirmed in clinical trials.

Downloads

pdf
Authors

Teresa Jimenez-Marco Fundació Banc de Sang i Teixits de les Illes Balears, Majorca, Spain; Grup de Investigació en Salut Pública de les Illes Balears (GISPIB), Institut d'Investigació Sanitària Illes Balears (IdISBa), Majorca, Spain ORCID

Natalia Torres-Reverte Fundació Banc de Sang i Teixits de les Illes Balears, Majorca, Spain

Miguel Quetglas-Oliver Departamento de Economía Aplicada, Universitat de les Illes Balears, Majorca, Spain ORCID

Daniel Morell-Garcia Servicio de Análisis Clínicos, Hospital Universitari Son Espases, Majorca, Spain

Carme Ballester-Servera Renal Lithiasis and Pathological Calcification Group, Research Institute of Health Sciences, IUNICS, University of the Balearic Islands, Palma, Spain; Health Research Institute of the Balearic Islands, Palma, Spain ORCID

  • Abstract viewed - 787 times
  • pdf downloaded - 0 times